In our study we assessed for the first time the expression of PU.1 in B cells derived from multiple biological compartments in RA patients finding that SF-derived CD19+ cells from RA patients show lower expression of PU.1 compared to healthy controls, consistently with miR-155 overexpression. This evidence concerns the gene CD19 and rheumatoid arthritis.